BACKGROUND: We used 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with soft tissue sarcoma (STS). Treatment effect was assessed with regard to prediction of therapy outcome. PATIENTS AND METHODS: The ongoing evaluation includes 27 patients with high-risk STS receiving chemotherapy consisting of doxorubicin and ifosfamide (AI-G regimen), or etoposide, ifosfamide and doxorubicin (EIA regimen). Patients were examined using PET prior to onset of therapy, and after completion of the first cycle of AI-G and after 2 cycles of EIA chemotherapy, respectively. Restaging according to RECIST was performed after 6 cycles of AI-G or 4 cycles of EIA chemotherapy and served as reference. RESULTS: Clinical outcome of 27 evaluable patients was as follows: 2 patients with no evidence of disease, 7 with partial remission, 14 with stable disease, and 4 patients with progressive disease. A significant difference of the progression-free survival for patients with a decrease in the standardised uptake value (SUV; responders) in comparison to patients with an increase or stable SUV (non-responders) could be demonstrated (p = 0.0187). CONCLUSION: On the basis of these data, prediction of chemo-sensitivity of the tumour and moreover of the therapy outcome might be possible. (c) 2008 S. Karger AG, Basel.
BACKGROUND: We used 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with soft tissue sarcoma (STS). Treatment effect was assessed with regard to prediction of therapy outcome. PATIENTS AND METHODS: The ongoing evaluation includes 27 patients with high-risk STS receiving chemotherapy consisting of doxorubicin and ifosfamide (AI-G regimen), or etoposide, ifosfamide and doxorubicin (EIA regimen). Patients were examined using PET prior to onset of therapy, and after completion of the first cycle of AI-G and after 2 cycles of EIA chemotherapy, respectively. Restaging according to RECIST was performed after 6 cycles of AI-G or 4 cycles of EIA chemotherapy and served as reference. RESULTS: Clinical outcome of 27 evaluable patients was as follows: 2 patients with no evidence of disease, 7 with partial remission, 14 with stable disease, and 4 patients with progressive disease. A significant difference of the progression-free survival for patients with a decrease in the standardised uptake value (SUV; responders) in comparison to patients with an increase or stable SUV (non-responders) could be demonstrated (p = 0.0187). CONCLUSION: On the basis of these data, prediction of chemo-sensitivity of the tumour and moreover of the therapy outcome might be possible. (c) 2008 S. Karger AG, Basel.
Authors: Dimosthenis Andreou; Henrike Boldt; Daniel Pink; Björn Jobke; Mathias Werner; Markus Schuler; Peter Reichardt; Per-Ulf Tunn Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-12 Impact factor: 9.236
Authors: Bernd Kasper; Thomas Schmitt; Patrick Wuchter; Antonia Dimitrakopoulou-Strauss; Anthony D Ho; Gerlinde Egerer Journal: Mar Drugs Date: 2009-07-17 Impact factor: 5.118
Authors: Bernd Kasper; Antonia Dimitrakopoulou-Strauss; Lothar R Pilz; Ludwig G Strauss; Christos Sachpekidis; Peter Hohenberger Journal: Biomed Res Int Date: 2013-05-16 Impact factor: 3.411
Authors: A C M van de Luijtgaarden; J W J de Rooy; L F de Geus-Oei; W T A van der Graaf; W J G Oyen Journal: Cancer Imaging Date: 2008-10-04 Impact factor: 3.909